A recent study published in the Journal of the National Cancer Institute found that lower doses of the human papillomavirus (HPV) vaccine Cervarix. This is important because if a person is exposed to less of a medication then there is less risk of an adverse event.
Cervarix is a HPV vaccine was designed to elicit an immune response against the human papillomavirus (HPV). It is manufactured by GlaxoSmithKline, and was FDA approved in October 2009. Cervarix and Gardasil are the two commercially available HPV vaccines.
To determine whether a lower number of doses of the Cervarix vaccine would be as effective, Aimée R. Kreimer, Ph.D., of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, and a team of researchers conducted an analysis of data from the NCI-sponsored Costa Rica Vaccine Trial, where women received either three doses of Cervarix or the control vaccine. Of the 7,466 women enrolled, 20% received fewer than three doses due to involuntary factors, such as pregnancy or referrals to colposcopy during routine patient management. The researchers compared the frequency of persistent infection with HPV 16 or 18 in the HPV and control arms of the trial during 4 years of follow-up in women who received one or two doses of the vaccine and in women who received 3 doses.
Once researchers excluded women who had no follow-up or who were HPV16 and HPV18 DNA positive at the time of enrollment, 5,967 women received three doses of the treatment, 802 received two doses and 384 women received only one dose.
The researchers found similar levels of protection against HPV16 and HPV18 from the vaccine among women receiving one, two, and three doses of the vaccine. For settings in which the cost of vaccine and logistics of implementation are important factors, they write, “Our clinical efficacy data provide suggestive evidence that an HPV vaccine program that provides fewer doses to more women could potentially reduce cervical cancer incidence more than a standard three-dose program that uses the same total number of doses but in fewer women.” They add that they were surprised by the evidence of protection from one dose, since other subunit vaccines typically require at least two shots. They caution that it remains to be determined whether fewer than three doses will provide strong protection for substantially longer periods than the 4 years of the current study.
They conclude, “If randomized studies and cost-effectiveness analyses confirm the benefits of administering fewer doses, and the duration of protection is sufficient, then the need for fewer doses may help make primary prevention of cervical cancer a reality.”
More studies are obviously needed in order to adequately determine the effectiveness of fewer doses.
GET HELP NOW!
You Only Have Three Years To File Your Claim
The first step in helping yourself or a loved one after a serious vaccine related injury is to contact us for a free review of your case.